[Pubmed] Muscle-Specific Receptor Tyrosine Kinase Antibody Positive Myasthenia Gravis

[RSS-Bot]

Brain Nerve. 2024 May;76(5):623-629. doi: 10.11477/mf.1416202652.

ABSTRACT

Reportedly, patients with muscle-specific kinase (MuSK) antibody-positive myasthenia gravis (MG) account for approximately 3.0% of all patients with MG in Japan. Compared with patients who have acetylcholine receptor antibody-positive MG, those with MuSK antibody-positive MG show young-onset disease with female predominance, a low rate of ocular involvement (5.9%), and greater severity of dysphagia. The aforementioned types of MG are indistinguishable based on clinical symptoms and electrophysiological tests, and measurement of MuSK antibodies is essential for diagnosis. Thymectomy and complement inhibitors are not indicated for treatment, and acetylcholinesterase inhibitors, steroids, immunosuppressants, plasma exchange, intravenous immunoglobulin therapy, and neonatal Fc receptor inhibitors are used.

PMID:38741505 | DOI:10.11477/mf.1416202652


Source: https://pubmed.ncbi.nlm.nih.gov/3874150 ... t9+e462414